News
08-27-2012, 12:20 AM
ImmunoGen, Inc., a biotechnology company that develops anticancer products using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced that Roche has reported that updated results from its EMILIA Phase III trial show that patients treated with trastuzumab emtansine had a significant improvement in OS compared to those randomized to standard-of-care therapy.
More... (http://www.news-medical.net/news/20120827/Results-from-Roches-trastuzumab-emtansine-Phase-III-trial-on-HER2-positive-breast-cancer.aspx)
More... (http://www.news-medical.net/news/20120827/Results-from-Roches-trastuzumab-emtansine-Phase-III-trial-on-HER2-positive-breast-cancer.aspx)